A narrative review published in Frontiers in Nutrition argues that the gradual loss of nicotinamide adenine dinucleotide (NAD+) metabolism sits near the center of brain aging, and that vitamin B3 metabolites, exercise and the gut microbiota all feed into the same pathway. It also says, repeatedly, that the clinical case is not made.

The compounds involved are the NAD+ precursors: nicotinic acid (niacin), nicotinamide (NAM), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NAD+ itself is a coenzyme used in redox reactions, mitochondrial energy production, DNA repair and calcium signaling, and the authors note that intracellular levels fall with age through both reduced biosynthesis and increased enzymatic consumption by sirtuins, PARPs and CD38.

Where the evidence actually sits

Most of what the review draws on is preclinical. The authors write that restoring NAD+ metabolism attenuated cognitive impairment, reduced neuronal loss and improved synaptic function in experimental models of Alzheimer's disease, then immediately add that whether this translates into clinically meaningful benefit in humans remains unclear. NR and NMN have drawn the most attention because early human studies reported increases in systemic NAD+ and favorable safety profiles, but the review says evidence on brain NAD+ availability and on cognitive outcomes is insufficient.

The mechanism is indirect

One of the more useful corrections here: the review insists these effects should not be read as direct actions of NAD+. The proposed neuroprotection runs through downstream enzymes and signaling, SIRT1, SIRT3, PARPs and AMPK, driving mitochondrial quality control, mitophagy, genomic stability and inflammatory resolution.

Exercise and the gut enter the same pathway

Exercise is framed as a physiological regulator of the same system, activating AMPK and sirtuin signaling, promoting mitochondrial biogenesis and regulating HIF-1alpha, which the authors say is required for exercise-induced neuroprotection in experimental work. Separately, emerging evidence suggests the gut microbiota contributes to NAD+ homeostasis by regulating vitamin B3 precursor availability and tryptophan metabolism.

Limitations

This is a review, not new data, and the underlying literature is weighted toward animal and cell models. The authors state that long-term efficacy and clinical relevance in neurodegenerative disease remain to be fully established, and that definitive therapeutic applications require further validation. Tissue-specific differences in NAD+ transport and precursor use may also mean systemic increases do not reach the brain.

Bottom line

The integrative framing is genuinely interesting, and the honesty about translation gaps is more than most supplement-adjacent literature offers. What is missing is the human trial data that would turn a mechanism into a therapy.